LOS ANGELES — The locker room after the Rams’ 37-20 loss to the Philadelphia Eagles was as quiet as any this season. Players shouldered blame in quiet, shorts responses to reporters’ questions before filing out and into the night. As they dissected what had just happened, the Rams (5-6) also looked ahead and stated they could not afford for this game to spiral into the next game, which is Sunday’s matchup with the New Orleans Saints (4-7). “Just make sure you turn the page. Obviously, there are things that we want to correct from the game and find ways to be better moving forward, but make sure that we come out with great energy today. It starts today,” Rams quarterback Matthew Stafford said before Wednesday’s practice. “There are going to be things we want to clean up from practice, make sure we do that and move on day-to-day with the right attitude and the right spirit.” As the Rams have gone about making those corrections, a consistent word has come to mind: Consistency. Asked what he’s looking for from the defense Sunday after its worst performance since the early weeks of the season, head coach Sean McVay used that word. He spoke about playing as a unit, sticking to assignments, coverage and pass rush complementing each other. Then he added with a smile, “Same things I’m looking for on the defense would be exactly how I would answer your offensive question as well.” Even 11 games into the season, we still haven’t seen the Rams offense perform with the type of consistency you would expect from a group with this much talent. Against the Eagles, the Rams moved the ball well in the first quarter, reaching the red zone twice without needing a third down. But any momentum was quickly lost with a 10-play second quarter that resulted in a loss of six yards. It was the same story a week before, with the offense blazing in the second and third quarters against the Patriots while going nowhere in the first and fourth quarters. “It’s kind of the word ‘consistency’ right now,” Rams offensive coordinator Mike LaFleur said. “There are times where it feels like we go right down the field and put it in, and there are other times where it just feels a little bit harder than it should. I think that’s the biggest key right now.” The defense is facing a similar obstacle. The Rams are among the best in the NFL at holding teams without a touchdown in the red zone, limiting opponents to a 48.8% success rate. That ranks eighth in the league, but the flip side is that the Rams allow teams 3.7 trips into the red zone per game, which is tied for 28th. Defensive tackle and captain Kobie Turner raised the issue of allowing too many long drives following the Eagles loss, and defensive coordinator Chris Shula agreed with the assessment. “Some of that, especially the other night, they were in third downs a decent amount of time and it was a third and favorable,” Shula said. “Then, finding a way to get stops, finding a way to play, get them off track, get them into 2nd-and-longs where you get those 3rd-longs, and you can earn the right to rush the passer.” Related Articles Entering Week 13, it’s not encouraging that the Rams are still struggling to find consistency in their execution. But to this point, it hasn’t upended their season. The wild card might be out of reach, but the NFC West title is still up for grabs. But that starts with a road win against a Saints team playing with nothing to lose. “We know that it’s going to be a great challenge, especially at their place. It’ll be rocking atmosphere and environment with the holidays and the momentum they have,” McVay said. “We’ve a lot of guys that are experiencing things for the first time. I have seen the resolve of this group show itself. Now, we’ve to do it.” When: 1:05 p.m. Sunday Where: Superdome, New Orleans TV/radio: FOX (Ch. 11)/710 AM; 93.1 FM; 1330 AM (Spanish); Sirius 382, 226

Dallas plays Winnipeg after Marchment's 2-goal performanceLOS ANGELES — The locker room after the Rams’ 37-20 loss to the Philadelphia Eagles was as quiet as any this season. Players shouldered blame in quiet, shorts responses to reporters’ questions before filing out and into the night. As they dissected what had just happened, the Rams (5-6) also looked ahead and stated they could not afford for this game to spiral into the next game, which is Sunday’s matchup with the New Orleans Saints (4-7). “Just make sure you turn the page. Obviously, there are things that we want to correct from the game and find ways to be better moving forward, but make sure that we come out with great energy today. It starts today,” Rams quarterback Matthew Stafford said before Wednesday’s practice. “There are going to be things we want to clean up from practice, make sure we do that and move on day-to-day with the right attitude and the right spirit.” As the Rams have gone about making those corrections, a consistent word has come to mind: Consistency. Asked what he’s looking for from the defense Sunday after its worst performance since the early weeks of the season, head coach Sean McVay used that word. He spoke about playing as a unit, sticking to assignments, coverage and pass rush complementing each other. Then he added with a smile, “Same things I’m looking for on the defense would be exactly how I would answer your offensive question as well.” Even 11 games into the season, we still haven’t seen the Rams offense perform with the type of consistency you would expect from a group with this much talent. Against the Eagles, the Rams moved the ball well in the first quarter, reaching the red zone twice without needing a third down. But any momentum was quickly lost with a 10-play second quarter that resulted in a loss of six yards. It was the same story a week before, with the offense blazing in the second and third quarters against the Patriots while going nowhere in the first and fourth quarters. “It’s kind of the word ‘consistency’ right now,” Rams offensive coordinator Mike LaFleur said. “There are times where it feels like we go right down the field and put it in, and there are other times where it just feels a little bit harder than it should. I think that’s the biggest key right now.” The defense is facing a similar obstacle. The Rams are among the best in the NFL at holding teams without a touchdown in the red zone, limiting opponents to a 48.8% success rate. That ranks eighth in the league, but the flip side is that the Rams allow teams 3.7 trips into the red zone per game, which is tied for 28th. Defensive tackle and captain Kobie Turner raised the issue of allowing too many long drives following the Eagles loss, and defensive coordinator Chris Shula agreed with the assessment. “Some of that, especially the other night, they were in third downs a decent amount of time and it was a third and favorable,” Shula said. “Then, finding a way to get stops, finding a way to play, get them off track, get them into 2nd-and-longs where you get those 3rd-longs, and you can earn the right to rush the passer.” Entering Week 13, it’s not encouraging that the Rams are still struggling to find consistency in their execution. But to this point, it hasn’t upended their season. The wild card might be out of reach, but the NFC West title is still up for grabs. But that starts with a road win against a Saints team playing with nothing to lose. “We know that it’s going to be a great challenge, especially at their place. It’ll be rocking atmosphere and environment with the holidays and the momentum they have,” McVay said. “We’ve a lot of guys that are experiencing things for the first time. I have seen the resolve of this group show itself. Now, we’ve to do it.” RAMS (5-6) at NEW ORLEANS SAINTS (4-7) When: 1:05 p.m. Sunday Where: Superdome, New Orleans TV/radio: FOX (Ch. 11)/710 AM; 93.1 FM; 1330 AM (Spanish); Sirius 382, 226

Greater Westside Board of Trade unveils new directors following AGM (West Kelowna)

The hematology market is experiencing significant growth driven by the increasing prevalence of blood-related disorders, advancements in research and product development, and the rising number of elderly individuals vulnerable to these conditions. Additionally, the growing adoption and awareness of minimally invasive procedures have further boosted the demand for hematology devices, supporting the market's expansion during the forecast period from 2024 to 2030. LAS VEGAS , Dec. 12, 2024 /PRNewswire/ -- DelveInsight's Hematology Market Insights report provides the current and forecast market analysis, individual leading hematology companies' market shares, challenges, hematology market drivers, barriers, trends, and key market hematology companies in the market. Key Takeaways from the Hematology Market Report As per DelveInsight estimates, North America is anticipated to dominate the global hematology market during the forecast period. In the type segment of the hematology market, coagulation analyzers are estimated to hold a higher share of the hematology market during the forecast period (2024-2030). Notable hematology companies such as Sysmex Corporation, Danaher, Nihon Kohden Corporation, Siemens Healthcare GmbH, Abbott, Boule Diagnostics, Bio-Rad Laboratories, Inc., Biosystems S.A., Diatron, EKF Diagnostics, Shenzhen Mindray Bio-Medical Electronics Co., Erba Mannheim , Ortho Clinical Diagnostics, Abaxis, Heska Corporation, F. Hoffmann-La Roche Ltd, Horiba Ltd., Neomedica, Thermo Fisher Scientific, Agilent, and several others, are currently operating in the hematology market. In December 2024 , Immune-Onc Therapeutics, Inc. shared updated results from its Phase 1b expansion cohort study of IO-202. This first-in-class anti-LILRB4 antibody was evaluated in combination with azacitidine (AZA) for the treatment of chronic myelomonocytic leukemia (CMML). The latest findings were presented during an oral session at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego, California . In December 2024 , BeiGene, Ltd. showcased new clinical data at the 66th American Society of Hematology (ASH) Annual Meeting, highlighting its leadership in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) through the ongoing clinical success of BRUKINSA (zanubrutinib) and notable progress in its pipeline developments. In December 2024 , Nurix Therapeutics, Inc. shared new encouraging clinical data from patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who were treated in the Phase 1a/ 1b clinical trial of its Bruton's tyrosine kinase (BTK) degrader, NX-5948. In December 2024 , Bristol Myers Squibb shared results from 18 presentations that underscore its leadership in cell therapy. The data highlighted the effectiveness, durability, and safety of existing therapies for blood cancers, while also showcasing the promise of its pipeline for future applications, including autoimmune diseases. These findings, which span a wide range of potential targets across various disease areas, were presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California . In December 2024 , Taiho Oncology, Inc. shared the findings of two studies on oral treatments for patients with myelodysplastic syndromes (MDS) and MDS/myeloproliferative neoplasm (MPN) at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH), held from December 7-10, 2024 , in San Diego . To read more about the latest highlights related to the hematology market, get a snapshot of the key highlights entailed in the Global Hematology Market Report Hematology Overview Hematology is a specialized branch of medicine that focuses on the study, diagnosis, treatment, and prevention of blood-related disorders and diseases. It encompasses a wide range of conditions, including anemia, clotting disorders, leukemia, lymphoma, and myeloma. Hematologists work to understand the intricate components of blood, such as red blood cells, white blood cells, platelets, hemoglobin, and plasma, as well as the organs responsible for blood production, like the bone marrow, lymph nodes, and spleen. The field is integral to understanding the body's immune system, oxygen transport, and coagulation processes, as these functions are closely tied to overall health. Advances in hematology, such as molecular diagnostics, targeted therapies, and bone marrow transplantation, have revolutionized the way hematologic diseases are managed. In recent years, hematology has witnessed significant breakthroughs, particularly in understanding the genetic and molecular basis of blood disorders. Cutting-edge therapies, including immunotherapy and gene editing technologies like CRISPR, are providing hope for patients with previously untreatable conditions. For instance, the development of antibody-drug conjugates and CAR-T cell therapies has improved outcomes for individuals with certain blood cancers. In addition, research into hematopoietic stem cell transplantation continues to expand, offering curative potential for diseases such as sickle cell anemia and severe aplastic anemia. As the field evolves, it not only enhances our understanding of blood and its disorders but also contributes to broader medical advancements in oncology, immunology, and regenerative medicine. Hematology Market Insights North America is anticipated to hold the largest share of the global hematology market. This dominance can be attributed to factors such as the growing prevalence of chronic blood disorders, a rising incidence of these conditions among the aging population, and advancements in product offerings, which collectively support the expansion of the hematology market in the region. The increasing number of blood disease cases underscores the demand for hematology in treatment, driving market growth in North America . Additionally, a strong focus on product innovation and the proactive efforts of device manufacturers to penetrate local markets through strategic partnerships contribute further to regional market development. These collaborations are likely to stimulate product demand. Consequently, a combination of factors—such as a large patient base, favorable reimbursement policies, and the introduction of new products—is expected to propel the growth of the North American hematology market during the forecast period. To know more about why North America is leading the market growth in the hematology market, get a snapshot of the Hematology Market Outlook Hematology Market Dynamics The hematology market has undergone significant evolution in recent years, driven by advancements in biotechnology, growing demand for precision medicine, and the increasing prevalence of hematologic disorders such as leukemia, lymphoma, and multiple myeloma. Hematology encompasses both diagnostics and therapeutics, making it a critical domain within healthcare. The rise in patient awareness and improvements in early detection technologies are boosting the diagnostic segment, while innovative treatments, including monoclonal antibodies, CAR-T therapies, and bispecific antibodies, dominate the therapeutic landscape. Additionally, the integration of genetic profiling into routine care has enabled tailored therapies, further propelling the market. One of the key dynamics shaping the hematology market is the shift towards targeted therapies , particularly for rare blood disorders and cancers. Traditional chemotherapies are being replaced or supplemented by highly specific treatments that minimize side effects and improve efficacy. In diseases like hemophilia, the adoption of gene therapies and recombinant products has been transformative. Similarly, the field of immuno-oncology is gaining traction, with treatments like immune checkpoint inhibitors and antibody-drug conjugates showing promise in hematologic malignancies. On the diagnostic side, the emergence of high-throughput technologies such as next-generation sequencing (NGS) and liquid biopsy has revolutionized disease detection and monitoring. These technologies allow for earlier diagnosis, better prognosis determination, and the ability to track disease progression or recurrence with higher accuracy. The growing demand for point-of-care (POC) diagnostics , especially in resource-limited settings, is further expanding the reach of hematology diagnostics to underserved populations. Despite these advances, the market faces several challenges, including high costs associated with novel therapies and diagnostics, regulatory hurdles, and access disparities , particularly in low- and middle-income countries. The complexity of personalized treatments also necessitates robust healthcare infrastructure, which is not uniformly available across regions. Furthermore, the market is highly competitive , with pharmaceutical and biotech companies vying for leadership in niche indications, leading to intense research and development (R&D) activities. Looking forward, the hematology market is expected to continue its growth trajectory, fueled by the integration of artificial intelligence (AI) and machine learning into research, diagnosis, and treatment development. These technologies have the potential to optimize patient outcomes and streamline healthcare delivery. Collaborations between academia, biotech firms, and pharmaceutical giants are likely to accelerate innovation, while regulatory frameworks are anticipated to evolve to better accommodate cutting-edge therapies. As the field advances, the hematology market remains a cornerstone of modern medicine, addressing unmet needs and improving quality of life for patients globally. Get a sneak peek at the hematology market dynamics @ Hematology Market Dynamics Analysis Hematology Market Assessment Hematology Market Segmentation Hematology Market Segmentation By Type: Instruments (Hematology Analyzers, Hematology Cell Counters, Flow Cytometers, Coagulation Analyzers, Others), Kits and Reagents Hematology Market Segmentation By Application: Cardiovascular Diseases, Auto-Immune Diseases, Cancer, Diabetes Mellitus, Infectious Diseases, Others Hematology Market Segmentation By Modality: Clinical Laboratory Devices, Point of Care Devices Hematology Market Segmentation By End User: Hospitals & Clinics, Diagnostic Laboratories, Others Hematology Market Segmentation By Geography : North America , Europe , Asia-Pacific , and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the hematology market are set to emerge as the trendsetter explore @ Hematology Companies Table of Contents Interested in knowing the hematology market by 2030? Click to get a snapshot of the Hematology Market Trends Related Reports Hematological Cancer Therapeutics Market Hematological Cancer Therapeutics Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key hematological cancer therapeutics companies, including Pfizer Inc., F. Hoffmann-LA Roche Ltd, Sanofi SA, Bristol-Myers Squibb Company, AbbVie Inc, Novartis AG, GlaxoSmithKline PLC, Amgen Inc., Takeda Pharmaceutical Co. Ltd, Johnson & Johnson, Incyte Corporation, AstraZeneca PLC, Celldex Therapeutics Inc., Kite Pharma (Gilead Sciences), Atara Biotherapeutics, Celgene Corporation, Astellas, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, among others. Coagulation Analyzers Market Coagulation Analyzers Market Insights, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key coagulation analyzers companies, including Abbott Laboratories Inc., Siemens Healthcare GmbH, Sysmex Corporation, Thermo Fisher Scientific Corporation, F. Hoffmann-La Roche Ltd., HORIBA Medical, Nihon Kohden Corporation, Maccura Biotechnology Co., Ltd., Bio-Group Medical System, Genrui Biotech Inc., A&T Corporation, Stago Group, Beijing Succeeder Technology Inc., Helena Laboratories Corporation, BPC BioSed S.R.L., Meril Life Sciences Pvt. Ltd., SCLAVO Diagnostics International, Erba Group, ACON Laboratories, Inc., Haemonetics Corporation , among others. Flow Cytometry Market Flow Cytometry Market Insights, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key flow cytometry companies, including Thermo Fisher Scientific Inc., BD, Stratedigm, Inc, Bio-Rad Laboratories, Inc., Luminex Corporation., Miltenyi Biotec, Sysmex Corporation, Agilent Technologies, Inc., Sony Biotechnology Inc., bioMérieux SA, Enzo Life Sciences, Inc., Union Biometrica, Inc., Cytek Biosciences, Sartorius AG, Beckman Coulter , Inc., Apogee Flow Systems Ltd., Molecular Instruments, Inc., Integrated DNA Technologies, Inc., New England Biolabs (NEB), ACROBiosystems , among others. Coagulation Factor Deficiency Market Coagulation Factor Deficiency Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key coagulation factor deficiency companies, including Novo Nordisk, Spark Therapeutics, Sanofi (Genzyme), Alnylam Pharmaceuticals, Pfizer, Biotest AG, Centessa Pharmaceuticals (Apcintex), Staidson Biopharma Inc., Ultragenyx Pharmaceutical, Bayer , among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur [email protected] +14699457679 https://www.delveinsight.com/medical-devices Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg SOURCE DelveInsight Business Research, LLP

Top war-crimes court issues arrest warrants for Netanyahu and others in Israel-Hamas fighting